ImmunoScape raises $11M to develop COVID-19 therapies

By The Science Advisory Board staff writers

August 12, 2020 -- ImmunoScape has raised $11 million in financing to research how T-cell immune response contributes to COVID-19 immunity, with the goal of aiding in vaccine and therapy development.

ImmunoScape is collaborating with several vaccine development companies, including the San Diego-based Arcturus, which is running clinical trials in Singapore.

Additionally, ImmunoScape will use the financing to continue enabling advanced immunotherapies for cancer. Anzu Partners led the financing round and was joined by the University of Tokyo Edge Capital in Japan and NPR Holdings in Indonesia.

AGC expands partnership with Novavax in U.S.
AGC Biologics is expanding its relationship with Novavax by increasing manufacturing of Novavax's Matrix-M adjuvant for the COVID-19 vaccine candidate...
Biosimulation can mitigate risk of COVID-19 drug development
Drug development can be an expensive and tedious process. Add in the urgency of the COVID-19 pandemic, and you have a recipe for frustration. Biosimulation...
COVID-19 vaccine based on peptide nanofibers shows promise
A new technology platform using self-assembling peptide nanofibers tagged with antibodies can be an effective SARS-CoV-2 vaccine, according to a proof-of-concept...
Novavax licenses COVID-19 vaccine to Takeda in Japan
Novavax and Takeda Pharmaceutical have formed a partnership for the development, manufacturing, and commercialization in Japan of NVX-CoV2373, Novavax's...
New COVID-19 vaccine candidate leverages earlier research
Could vaccine platforms developed for previous coronaviruses be converted to address the current COVID-19 pandemic? An August 5 report in Nature...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter